A Gene-Based Aesthetics Company

Learn More
Not an actual patient
INNOVATIVE AND DIFFERENTIATED APPROACH ADDRESSES UNDERLYING BIOLOGY CLINICALLY VALIDATED TECHNOLOGY

About Us

Jeune Inc. is a biotechnology company leveraging a clinically validated gene-delivery platform to fundamentally address – and reverse – the biology of aging or photo-damaged skin.
Jeune was formed in April 2019 by Krystal Biotech to advance a portfolio of innovative treatments that address aesthetic skin conditions. Our product candidates are based on Krystal’s Skin TARgeted Delivery platform, or STAR-D platform. This skin-optimized gene delivery technology enables us to specifically target key cells in the skin for delivery of a desired effector (gene). In doing so, we aim to stimulate a patient’s own cells to produce the important structural proteins that normally decline over time as we age (intrinsic aging) and with photo-damage (extrinsic aging).
Learn More

Our Science

Changes in the amount and organization of important proteins, like collagen and elastin, are the primary factor in the appearance of aging or damaged skin.
Current treatments artificially address these changes by “freezing” the face or adding artificial volume. Jeune’s pipeline of innovative treatments are designed to directly address the biology of aging skin by stimulating a patient’s own cells to produce the proteins that keep skin looking younger and healthier.
scientist holding a beaker

Publications
and Presentations

Our Pipeline

Program
Indication
Protein
Discovery
IND Enabling
Clinical Dev
KB301
aesthetic skin conditions
type III collagen
KB302
TBA
type I collagen
KB303
TBA
elastin
KB304
TBA
type III collagen + elastin

Jeune Team

Bhushan Hardas
President, Jeune Inc.
Krish Krishnan
Board Member
Suma Krishnan
Board Member
Marc Forth
Board Member

News

Contact Us

Top